FIELD: organic chemistry; pharmacology; medicine.
SUBSTANCE: group of inventions includes individual compounds specified in the claim, a pharmaceutical composition containing them, and use thereof.
EFFECT: compounds given in the claim for inhibiting human cytochrome P450 11B2 (CYP11B2) activity and reducing the level of the hormone aldosterone.
8 cl, 3 tbl, 28 ex
Title | Year | Author | Number |
---|---|---|---|
HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2022 |
|
RU2811745C1 |
HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2023 |
|
RU2824362C1 |
HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2789610C1 |
HUMAN CYTOCHROME 11B2 INHIBITORS | 2021 |
|
RU2783521C1 |
HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2800378C1 |
ALDOSTERONE SYNTHASE INHIBITORS BASED ON 2-AMINO-4H-PYRAN-3-CARBONITRILE DERIVATIVES | 2019 |
|
RU2717310C1 |
NOVEL 3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONES AND 2,3-DIHYDRO-ISOINDOLE-1-ONES | 2014 |
|
RU2689421C2 |
INHIBITOR OF CERTAIN PROTEIN KINASES | 2016 |
|
RU2732952C2 |
SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | 2013 |
|
RU2607081C2 |
BROMDOMAIN INHIBITORS | 2012 |
|
RU2671571C1 |
Authors
Dates
2024-12-02—Published
2023-08-07—Filed